U.S. Oncology to launch term B repricing Wednesday

By Sara Rosenberg

New York, Nov. 16 - U.S. Oncology Inc. is scheduled to hold a conference call on Wednesday to launch a repricing of its term loan B that would lower the interest rate to Libor plus 225 basis points from Libor plus 275 basis points, according to a market source.

Furthermore, under the repricing proposal, there would be a step down to Libor plus 200 basis points once the company gets BB ratings, the source added.

JPMorgan Chase Bank, Wachovia Bank and Citicorp North America Inc. were the lead banks on the Houston cancer-care services company's deal when it was first obtained in August.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.